Skip to main content
logo
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.45
+1.03 (4.81%)
At close: Apr 2, 2026, 4:00 PM EDT
22.45
0.00 (0.00%)
After-hours: Apr 2, 2026, 4:11 PM EDT

Ultragenyx Pharmaceutical Revenue

In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth. Ultragenyx Pharmaceutical had revenue of $207.28M in the quarter ending December 31, 2025, with 25.89% growth.

Revenue (ttm)
$673.00M
Revenue Growth
+20.18%
P/S Ratio
3.22
Revenue / Employee
$490,883
Employees
1,371
Market Cap
2.20B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025673.00M113.00M20.18%
Dec 31, 2024560.00M126.00M29.03%
Dec 31, 2023434.00M70.67M19.45%
Dec 31, 2022363.33M11.92M3.39%
Dec 31, 2021351.41M80.38M29.66%
Dec 31, 2020271.03M167.32M161.32%
Dec 31, 2019103.71M52.22M101.41%
Dec 31, 201851.50M48.88M1,871.48%
Dec 31, 20172.61M2.48M1,863.91%
Dec 31, 2016133.00K--
Dec 31, 2015---
Dec 31, 2014---
Dec 31, 2013---
Dec 31, 2012---
Dec 31, 2011---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Galapagos NV1.31B
ADMA Biologics510.17M
Zai Lab460.16M
Aurinia Pharmaceuticals283.06M
Adaptive Biotechnologies276.98M
Syndax Pharmaceuticals172.35M
Viridian Therapeutics70.85M
Nektar Therapeutics55.23M
Revenue Rankings

RARE News

More News